Protective effects of the angiotensin II receptor blocker losartan on cisplatin-induced kidney injury

Chemotherapy

Volumn 55, Issue 6, 2009, Pages 399-406

  Saleh, Samira ^a   Ain Shoka, Afaf A ^a   El Demerdash, Ebtehal ^b   Khalef, Marwa M ^c  

^a CAIRO UNIVERSITY   (Egypt)

^b AIN SHAMS UNIVERSITY   (Egypt)

^c Beni Suef University   (Egypt)

Author keywords

Cisplatin; Losartan; Nephrotoxicity; Oxidative stress; Rat kidney sections; Renal cortical slices

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CISPLATIN; CREATININE; GLUTATHIONE; LACTATE DEHYDROGENASE; LIPID PEROXIDE; LOSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG UPTAKE; HISTOPATHOLOGY; KIDNEY CORTEX; KIDNEY INJURY; LIPID PEROXIDATION; MALE; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RENAL PROTECTION; SINGLE DRUG DOSE; UREA NITROGEN BLOOD LEVEL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD UREA NITROGEN; CISPLATIN; CREATININE; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; GLUTATHIONE; KIDNEY DISEASES; L-LACTATE DEHYDROGENASE; LIPID PEROXIDATION; LOSARTAN; MALE; OXIDATIVE STRESS; RATS;

EID: 70849099078     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000262453     Document Type: Article

References (44)

1. Giachelli CM, Pichler R, Lombardi D, Denhardt DT, Alpers CE, Schwarz SM, Johnson RJ: Osteopontin expression in angiotensin II-induced tubulointerstitial nephritis. Kidney Int 1994; 45:515-524.
2. Hannken T, Schroeder R, Stahl RA, Wolf G: Angiotensin II-mediated expression of p27 Kip1 and induction of cellular hypertrophy in renal tubular cells depend on the generation of oxygen free radicals. Kidney Int 1998; 54: 1923-1933.
3. Padi SSV, Chopra K: Selective angiotensin II type 1 receptor blockade ameliorates cyclosporine nephrotoxicity. Pharmacol Res 2002; 45: 413-420.
4. Burdmann EA, Andoh TF, Nast CC, Evan A, Connors BA, Coffman TM, Lindsley J, Bennett WM: Prevention of experimental cyclosporine- induced interstitial fibrosis by losartan and enalapril. Am J Physiol 1995; 269: F491-F499.
5. Somali I, Alacacioglu A, Tarhan MO, Meydan N, Erten C, Usalp S, Yilmaz U: Cisplatin plus gemcitabine chemotherapy in taxane/ anthracycline-resistant metastatic breast cancer. Chemotherapy 2009; 55: 155-160.
6. Livingston RB: Cisplatin in the treatment of solid tumors: effect of dose and schedule. J Natl Cancer Inst 1989; 81: 724-725.
7. Pabla N, Dong Z: Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 2008; 73: 994-1007.
8. Sayed-Ahmed MM, Eissa MA, Kenawy SA, Mostafa N, Calvani M, Osman AM: Progression of cisplatin-induced nephrotoxicity in a carnitine-depleted rat model. Chemotherapy 2004; 50: 162-170.
9. Saleh S, El-Demerdash E: Protective effects of L -arginine against cisplatin-induced renal oxidative stress and toxicity: role of nitric oxide. Basic Clin Pharmacol Toxicol 2005; 97: 91-97.
10. Francescato HDC, Cosat RS, Camargo SMR, Zanetti MA, Lavrador MA, Bianchi MLP: Effect of dietary oral selenium on cisplatininduced nephrotoxicity in rats. Pharmacol Res 2001; 43: 77-82.
11. Dumas M, DeGismain C, d'Athis P, Chadoint- Noudeau V, Escousse A, Guerrin J: Evaluation of the effect of furosemide on ultrafilterable platinum kinetics in patients treated with cis-diamminedichloroplatinum. Cancer Chemother Pharmacol 1989; 23: 37-40.
12. Ormond PM, Hande KR: Atrial natriuretic peptide protects against cisplatin nephrotoxicity in rats. Proc Am Assoc Cancer Res 1992; 33: 534.
13. Deegan PM, Basinger MA, Jones MM, Hande KR: Atrial natriuretic peptide reduces the nephrotoxicity but not the anti-tumor activity of cisplatin. Br J Pharmacol 1992; 107: 40.
14. Harris PG, Thomas D, Morgan TO: Atrial natriuretic peptide inhibits angiotensinstimulated proximal tubular sodium and water reabsorption. Nature 1987; 326: 697-698.
15. Brenneke HJ, Weinknecht S, Finck GA, Mitlehner W, Weissbach L: Rare metabolic and cerebral complications after polychemotherapy of a testicular tumor. Urologe A 1994; 33: 484-486.
16. Kurt E, Manavoglo O, Dilek K, Orhan B, Evrensel T: Effect of cisplatin on plasma renin activity and serum aldosterone levels. Clin Nephrol 1999; 52: 397-398.
17. Saleh S, Ain-Shoka AA, El-Demerdash E, Khalef MM: Insights into potential protective mechanisms of captopril aginst cisplatin-induced nephrotoxicity in the rat: in vivo and in vitro studies. Pak J Pharm Sc, in press.
18. Herblin WF, Chiu AT, McCall DE, Ardecky RJ, Carini DJ, Duncia JV, Pease LJ, Wong PC, Wexler RR, Johnson AJ, Timmermans PBMWM: Angiotensin II receptor heterogeneity. Am J Hypertens 1991; 4: 299s-302s.
19. Raya TE, Fonken SJ, Lee RW, Daugherty S, Goldman S, Wong PC, Timmermans PBMWM, Morkin I: Hemodynamic effects of direct angiotensin II blockade compared to converting enzyme inhibition in rat model of heart failure. Am J Hypertens 1991; 4: 334s-340s.
20. Deegan PM, Nolan C, Ryan MP, Basinger MA, Jones MM, Hande KR: The role of the renin-angiotensin system in cisplatin nephrotoxicity. Ren Fail 1995; 17: 665-674.
21. Guarino AM, Miller DS, Arnold ST, Pritchard JB, Davis RD, Urbanek MA, Miller TJ, Litters CL: Platinate toxicity: past, present, and prospects. Cancer Treat Rep 1979; 63: 1475-1483.
22. Ruegg CE, Gandolfi AJ, Nagle RB, Krumdieck L, Brendel K: Preparation of positional renal slices for study of cell-specific toxicity. J Pharmacol Methods 1987; 17: 111-123.
23. Jones MM, Basinger MA, Beaty JA, Holscher MA: The relative nephrotoxicity of cisplatin, cis-[Pt(NH 3 ) 2 (guanosine) 2 ] and the hydrolysis product of cisplatin in the rat. Cancer Chemother Pharmacol 1991; 29: 29-32.
24. Zhang JG, Zhong LF, Zhang M, Xia YX: Protection effects of procaine on oxidative stress and toxicities of renal cortical slices from rats caused by cisplatin in vitro. Arch Toxicol 1992; 66: 354-358.
25. Fabiny DL, Ertingshausen G: Automated reaction rate method for determination of serum creatinine with the CentrifiChem. Clin Chem 1971; 17: 696-700.
26. Patton CJ, Crouch SR: Spectrophotometric and kinetics investigation of the Berthelot reaction for the determination of ammonia. Anal Chem 1977; 49: 464-469.
27. Leathwood PD, Gilford MK, Plummer DT: Enzymes in rat urine: lactate dehydrogenase. Enzymologica 1972; 42: 285-301.
28. Ohkawa H, Ohishi N, Yagi K: Assay of lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351-358.
29. Ellman GL: Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 74: 214-226.
30. Al-Yazigi A, Al-Saleh I: Rapid determination of platinum by flameless atomic absorption spectrophotometry following the administration of cisplatin to cancer patients. Ther Drug Monit 1986; 8: 318-320.
31. Anderson S, Komers R: Inhibition of the renin- angiotensin system: is more better? Kidney Int 2009; 75: 12-14.
32. Teles F, Machado FG, Ventura BH, Malheiros DM, Fujihara CK, Silva LF: Regression of glomerular injury by losartan in experimental diabetic nephropathy. Kidney Int 2009; 75: 72-79.
33. Kuhlmann MK, Burkhardt G, Kohler H: Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol Dial Transplant 1997; 12: 2478-2480.
34. Naziroglu M, Karaoglu A, Aksoy AO: Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicology 2004; 195: 221-230.
35. Conklin KA: Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutr Cancer 2000; 37: 1-18.
36. Zhang JG, Lindup WE: Role of mitochondria in cisplatin-induced oxidative damage exhibited by rat renal cortical slices. Biochem Pharmacol 1993; 45: 2215-2222.
37. Zhang JG, Lindup WE: Tiopronin protects against the nephrotoxicity of cisplatin in rat renal cortical slices in vitro. Toxicol Appl Pharmacol 1996; 141: 425-433.
38. Braunlich H, Appenroth D, Fleck C: Protective effects of methimazole against cisplatininduced nephrotoxicity in rats. J Appl Toxicol 1997; 17: 41-45. (Pubitemid 27091396)
39. Osman AM, El-Sayed EM, El-Demerdash E, Al-Hyder A, Attia AS, Hamada FM: Prevention of cisplatin-induced nephrotoxicity by methimazole. Pharmacol Res 2000; 41: 115-121.
40. Mistry P, Merazga Y, Spargo DJ, Rileey PA, McBrien DCH: The effects of cisplatin on the concentration of protein thiols and glutathione in the rat kidney. Cancer Chemother Pharmacol 1991; 28: 277-282.
41. Vaziri ND, Bai Y, Ni Z, Quiroz Y, Pandian R, Rodriguez-Iturbe B: Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation and progressive injury in renal mass reduction. J Pharmacol Exp Ther 2007; 323: 85-93.
42. Portero-Otin M, Pamplona R, Boada J, Jove M, Gonzalo H, Buleon M, Linz W, Schafer S, Tack I, Girolami JP: Inhibition of renin angiotensin system decreases renal protein oxidative damage in diabetic rats. Biochem Biophys Res Commun 2008; 368: 528-535.
43. Hanneman J, Baumann K: Nephrotoxicity of cisplatin, carboplatin and transplatin: a comparative in-vitro study. Arch Toxicol 1990; 64: 393-400.
44. Jacobs C, Kaubisch S, Halsey J, Lum BL, Gosland M, Coleman CN, Sikic BI: The use of probenecid as a chemoprotector against cisplatin nephrotoxicity. Cancer 1991; 67: 1518-1524.